- Home
- ZVIA vs NBTX Comparison
ZVIA vs NBTX Comparison
Compare ZVIA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- NBTX
- Stock Information
- Founded
- ZVIA 2007
- NBTX 2003
- Country
- ZVIA United States
- NBTX France
- Employees
- ZVIA N/A
- NBTX N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- NBTX Health Care
- Exchange
- ZVIA Nasdaq
- NBTX Nasdaq
- Market Cap
- ZVIA 166.5M
- NBTX 167.8M
- IPO Year
- ZVIA 2021
- NBTX 2020
- Fundamental
- Price
- ZVIA $3.14
- NBTX $4.48
- Analyst Decision
- ZVIA Hold
- NBTX Strong Buy
- Analyst Count
- ZVIA 2
- NBTX 1
- Target Price
- ZVIA $3.38
- NBTX $8.00
- AVG Volume (30 Days)
- ZVIA 523.9K
- NBTX 9.0K
- Earning Date
- ZVIA 08-06-2025
- NBTX 04-02-2025
- Dividend Yield
- ZVIA N/A
- NBTX N/A
- EPS Growth
- ZVIA N/A
- NBTX N/A
- EPS
- ZVIA N/A
- NBTX N/A
- Revenue
- ZVIA $154,273,000.00
- NBTX N/A
- Revenue This Year
- ZVIA $5.66
- NBTX N/A
- Revenue Next Year
- ZVIA $6.76
- NBTX $221.06
- P/E Ratio
- ZVIA N/A
- NBTX N/A
- Revenue Growth
- ZVIA N/A
- NBTX N/A
- 52 Week Low
- ZVIA $0.62
- NBTX $2.76
- 52 Week High
- ZVIA $4.99
- NBTX $6.00
- Technical
- Relative Strength Index (RSI)
- ZVIA 63.24
- NBTX 51.68
- Support Level
- ZVIA $2.89
- NBTX $4.18
- Resistance Level
- ZVIA $3.27
- NBTX $5.76
- Average True Range (ATR)
- ZVIA 0.19
- NBTX 0.24
- MACD
- ZVIA 0.04
- NBTX -0.06
- Stochastic Oscillator
- ZVIA 76.79
- NBTX 21.69
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.